Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 29 March 2017, 10:09 HKT/SGT
Share:
    

Source: Eisai
Enrollment Commences in Phase III Clinical Study of Eisai's Bace Inhibitor Elenbecestat in Early Alzheimer's Disease in Japan

TOKYO, Mar 29, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that enrollment has commenced in Japan for MISSION AD1, a global Phase III clinical study of the in-house developed oral beta secretase cleaving enzyme (BACE) inhibitor elenbecestat(1) (development code: E2609) in patients with early Alzheimer's disease (AD).

The Phase III clinical trial program for elenbecestat (MISSION AD) consists of two global Phase III clinical studies with the same protocols, MISSION AD1 (Study 301) and MISSION AD2 (Study 302). Both studies are multicenter, placebo-controlled, double-blind, parallel-group Phase III clinical studies aiming to assess the efficacy and safety of elenbecestat for treatment of early AD, including mild cognitive impairment due to AD and a subset of very mild AD, in 1,330 patients with positive biomarkers for brain amyloid pathology. Patients are administered a dosage of 50 mg of elenbecestat daily during the treatment period of 24 months, and the primary endpoint will utilize the Clinical Dementia Rating Sum of Boxes (CDR-SB). MISSION AD1 commenced first in the U.S. in October 2016 and the enrollment has been progressing steadily. MISSION AD2 commenced in the U.S in December 2016, and will commence in Japan shortly. Additionally, in Europe, applications for both clinical studies have been submitted, and preparations to begin are underway.

Elenbecestat is an oral BACE inhibitor currently being investigated in Phase III clinical studies for AD. By inhibiting BACE, a key enzyme in the production of Aβ peptides, elenbecestat reduces Aβ production, which is thought to lead to a reduction in amyloid plaque formations caused by the aggregation of toxic oligomers and protofibrils in the brain. Elenbecestat is being jointly developed by Eisai and Biogen Inc. In addition, the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of elenbecestat, a process allowing priority reviews by the FDA for drugs deemed to treat serious conditions and tackle key unmet medical needs.

Juntendo University, School of Medicine Professor Heii Arai, M.D., Ph.D., who is serving as an advisory board member for MISSION AD in Japan, commented, "Including Japan, populations are aging worldwide, and along with that, the number of dementia and mild cognitive impairment patients are increasing significantly and this is an important issue. Through the MISSION AD clinical studies, development of the Japanese-originated BACE inhibitor for the suppression of Abeta production will be further advanced, and I anticipate that it will contribute to patients with early AD."

(1) The generic name is not yet fixed at this time.

About the Joint Development Agreement between Eisai and Biogen

Based on the collaboration agreement, Eisai will serve as the operational and regulatory lead in the co-development of elenbecestat, a BACE inhibitor, and BAN2401, an anti-amyloid beta (Abeta) protofibril antibody, and will pursue marketing authorizations for both compounds worldwide. If approved, the companies will also co-promote the products, in major markets, such as the United States, the European Union and Japan. Both companies will equally split overall costs, including research and development expenses. Eisai will book all sales for elenbecestat and BAN2401 following marketing approval and launch, and profits will be equally shared between the companies. Also, Eisai has received from Biogen an upfront payment as well as the right to receive additional development, approval and commercial milestone payments. Under the same agreement, Eisai also holds options to jointly develop and commercialize two of Biogen's investigational treatments for Alzheimer's disease, the anti-Aβ antibody aducanumab and an anti-tau antibody.


About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120


Mar 29, 2017 10:09 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2017 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Apr 19, 2017 12:21 HKT/SGT
Eisai Announces Results and Continued Support of Initiatives for Elimination of Lymphatic Filariasis
Apr 11, 2017 11:42 HKT/SGT
Eisai to Launch "Chocola BB Gold Rich" Highest Combination of Active Ingredients in Chocola BB Series
Apr 5, 2017 10:23 HKT/SGT
Eisai and Meiji Enter Into Licensing Agreement Concerning Parkinson's Disease Drug Safinamide in Japan and Asia
Apr 5, 2017 10:12 HKT/SGT
Eisai Presents Data of Mechanisms of Action Relating to Tumor Immune Response Regarding Combination of Anticancer Agent Lenvatinib With Anti-PD-1 Antibody at AACR 108th Annual Meeting
Apr 4, 2017 08:56 HKT/SGT
Eisai to Launch Smell Identification Test UPSIT Series in Japan
Mar 29, 2017 09:08 HKT/SGT
German Federal Joint Committee (G-Ba) Confirms Additional Benefit of Anticancer Agent Kisplyx (Lenvatinib Mesylate) in Treatment of Advanced Renal Cell Carcinoma
Jan 25, 2017 07:59 HKT/SGT
Phase III Trial of Anticancer Agent Lenvima as First-Line Treatment for Unresectable Hepatocellular Carcinoma Meets Primary Endpoint
Jan 24, 2017 17:43 HKT/SGT
Eisai Selected for Excellence in Sustainability Performance and Industry Mover Distinction by Robecosam
Jan 18, 2017 13:23 HKT/SGT
Eisai to Participate in Access Accelerated, Global Partnership to Address Rise of Non-Communicable Diseases
Jan 16, 2017 08:19 HKT/SGT
Transfer of Rights to Insomia Treatment / Anaesthesia Induction Agent Flunitrazepam in Japan
More news >>
 News Alerts
Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: